Ubs Asset Management Americas Inc Vertex Pharmaceuticals Inc Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,329,219 shares of VRTX stock, worth $1.11 Billion. This represents 0.22% of its overall portfolio holdings.
Number of Shares
2,329,219
Previous 2,441,468
4.6%
Holding current value
$1.11 Billion
Previous $1.14 Billion
17.39%
% of portfolio
0.22%
Previous 0.3%
Shares
29 transactions
Others Institutions Holding VRTX
# of Institutions
1,753Shares Held
227MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.4 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.1 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.68 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$4.95 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $122B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...